204140-01-2 Usage
Description
MMP-9/MMP-13 INHIBITOR I is a cell-permeable inhibitor of matrix metalloproteinases (MMPs) that most potently inhibits MMP-9 and MMP-13 (IC50s = 0.9 nM for both). It is a piperazine-based, highly potent inhibitor used to elucidate the roles of MMPs in biological systems, including tumor cell invasion and pathogenesis of P. falciparum.
Uses
Used in Pharmaceutical Industry:
MMP-9/MMP-13 INHIBITOR I is used as a research tool for studying the functions and roles of MMP-9 and MMP-13 in various biological processes. Its high potency and selectivity make it a valuable compound for investigating the involvement of these specific MMPs in diseases such as cancer, arthritis, and other inflammatory conditions.
Used in Cancer Research:
MMP-9/MMP-13 INHIBITOR I is used as an inhibitor for cancer research, specifically targeting the MMP-9 and MMP-13 enzymes that play a role in tumor cell invasion and metastasis. By inhibiting these enzymes, researchers can study the effects on cancer progression and develop potential therapeutic strategies for cancer treatment.
Used in Arthritis and Inflammatory Disease Research:
MMP-9/MMP-13 INHIBITOR I is used as a therapeutic agent in the study of arthritis and other inflammatory diseases, where MMP-9 and MMP-13 are implicated in the breakdown of cartilage and extracellular matrix. Inhibiting these enzymes may help in understanding the disease mechanisms and developing potential treatments to reduce inflammation and joint damage.
Check Digit Verification of cas no
The CAS Registry Mumber 204140-01-2 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 2,0,4,1,4 and 0 respectively; the second part has 2 digits, 0 and 1 respectively.
Calculate Digit Verification of CAS Registry Number 204140-01:
(8*2)+(7*0)+(6*4)+(5*1)+(4*4)+(3*0)+(2*0)+(1*1)=62
62 % 10 = 2
So 204140-01-2 is a valid CAS Registry Number.
204140-01-2Relevant articles and documents
Development of piperazine-based hydroxamic acid inhibitors against falcilysin, an essential malarial protease
, p. 1846 - 1848 (2018)
The human parasite Plasmodium falciparum kills an estimated 445,000 people a year, with the most fatalities occurring in African children. Previous studies identified falcilysin (FLN) as a malarial metalloprotease essential for parasite development in the
